Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Depreciation and Depletion: 2019-2024

Historic Depreciation and Depletion for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Dec 2024 value amounting to $700,000.

  • Tarsus Pharmaceuticals' Depreciation and Depletion changed negligibly% to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $820,000, marking a year-over-year increase of 10.22%. This contributed to the annual value of $700,000 for FY2024, which is 5.91% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Depreciation and Depletion of $700,000 as of FY2024, which was down 5.91% from $744,000 recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Depreciation and Depletion ranged from a high of $744,000 in FY2023 and a low of $100,000 during FY2020.
  • Over the past 3 years, Tarsus Pharmaceuticals' median Depreciation and Depletion value was $700,000 (recorded in 2024), while the average stood at $590,000.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Depreciation and Depletion spiked by 200.00% in 2021 and then fell by 5.91% in 2024.
  • Tarsus Pharmaceuticals' Depreciation and Depletion (Yearly) stood at $100,000 in 2020, then surged by 200.00% to $300,000 in 2021, then rose by 8.67% to $326,000 in 2022, then spiked by 128.22% to $744,000 in 2023, then dropped by 5.91% to $700,000 in 2024.